Onishi T, Fukuda Y, Miyazaki S, et al. Practical guidance for echocardiography for cancer therapeutics-related cardiac dysfunction. J Echocardiogr. 2021;19:1–20.

Article  PubMed  Google Scholar 

Okura Y, Ozaki K, Tanaka H, et al. The impending epidemic of cardiovascular diseases in patients with cancer in Japan. Circ J. 2019;83:2191–202.

Article  PubMed  Google Scholar 

Ball S, Ghosh RK, Wongsaengsak S, et al. Cardiovascular toxicities of immune checkpoint inhibitors. J Am Coll Cardiol. 2019;74:1714–27.

Article  CAS  PubMed  Google Scholar 

Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6:38.

Article  PubMed Central  PubMed  Google Scholar 

Takahashi T, Tagami T, Yamazaki T, et al. Immunologic self-tolerance maintained by CD25(+) CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192:303–10.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Kadowaki H, Akazawa H, Ishida J, Komuro I. Mechanisms and management of immune checkpoint inhibitor-related cardiac adverse events. JMA J. 2021;4:91–8.

Article  PubMed Central  PubMed  Google Scholar 

Tajiri K, Aonuma K, Sekine I. Immune checkpoint inhibitor-related myocarditis. Jpn J Clin Oncol. 2018;48:7–12.

Article  PubMed  Google Scholar 

Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579–89.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Ederhy S, Dolladille C, Thuny F, et al. Takotsubo syndrome in patients with cancer treated with immune checkpoint inhibitors: a new adverse cardiac complication. Eur J Heart Fail. 2019;21:945–7.

Article  PubMed  Google Scholar 

Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–55.

Article  PubMed Central  PubMed  Google Scholar 

Mahmood SS, Fradley MG, Cohen HV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71:1755–64.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4:1721–8.

Article  PubMed Central  PubMed  Google Scholar 

Escudier M, Cautela J, Malissen N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136:2085–7.

Article  PubMed  Google Scholar 

Hu JR, Florido R, Lipson EJ, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115:854–68.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Palaskas N, Morgan J, Daigle T, et al. Targeted cancer therapies with pericardial effusions requiring pericardiocentesis focusing on immune checkpoint inhibitors. Am J Cardiol. 2019;123:1351–7.

Article  PubMed  Google Scholar 

Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229–361.

Article  PubMed  Google Scholar 

Rini B, Moslehi JJ, Bonaca M, et al. Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell cancer: data from the phase 3 JAVELIN Renal 101 trial. J Clin Oncol. 2022;40:1929–38.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Awadalla M, Mahmood SS, Groarke JD, et al. Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. J Am Coll Cardiol. 2020;75:467–78.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Tanabe J, Watanabe N, Endo A, et al. Asymptomatic immune checkpoint inhibitor-associated myocarditis. Intern Med. 2021;60:569–73.

Article  PubMed  Google Scholar 

Tamura Y, Tamura Y, Takemura R, et al. Longitudinal strain and troponin I elevation in patients undergoing immune checkpoint inhibitor therapy. JACC CardioOncol. 2022;4:673–85.

Article  PubMed Central  PubMed  Google Scholar 

Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36:1714–68.

Article  CAS  PubMed  Google Scholar